Tactile Systems opened lower at $27.11, compared with its previous close of $27.13. In the last trading session, the stock traded between $26.73 and $27.25. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Tactile Systems is now worth
$ 90.17
Resulting in a loss of
$ 9.83 (9.83%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.29 (-1.08%)
Day High
$27.25
Day Low
$26.73
Day Open
$27.11
Prev Close
$27.13
Volume
1,58,412
1W Return
-1.55%
1M Return
18.43%
3M Return
10.99%
6M Return
12.28%
1Y Return
6.92%
Market Cap ($ Mn)
601
PE Ratio
21.45
PB Ratio
2.35
PEG Ratio
2.37
ROE
9.17%
ROCE
12.33%
EPS (TTM)
$0.32
1 Week
-1.55%
1 Month
18.43%
3 Months
10.99%
6 Months
12.28%
9 Months
-2.84%
BTIG maintains Buy on Tactile Systems, lowers price target to $31
BTIG maintained a Buy rating on Tactile Systems Technology Inc. Price target lowered from $35 to $31 by analyst Ryan Zimmerman. No change in investment recommendation status.
9 days agoTactile Systems Technology Q3FY26 Results: Revenue $91.9M, EBITDA guidance raised
Tactile Systems Technology reported Q3 2026 total revenue of $91.9 million, up 7.1% YoY, driven by 13.1% growth in lymphedema revenue to $81.8 million. Airway clearance revenue fell 25.1% YoY to $10 million due to a one-time DME inventory transition related to the next-generation AffloVest launch. Gross margin expanded 90 bps YoY to 76.7%, marking the 12th consecutive quarter of year-over-year gross margin expansion. Full-year 2026 adjusted EBITDA guidance raised to $50 to $52 million, representing approximately 12% to 16% growth vs $44.8 million in 2025; revenue guidance maintained at $360 to $366 million. FDA 510(k) clearance received for an expanded indication of the LymphaTech 3D scanner; Flexitouch Pro 510(k) application filed in October with a commercial launch targeted for second half of 2027.
10 days agoTactile Medical to release Q3 FY26 financial results on November 2
Q3 FY26 results scheduled for November 2, 2026. Conference call set for 5:00 pm ET same day. Replay available for two weeks post-call. Focus on chronic disorder therapies.
24 days agoTactile Medical Q2 profit jumps 142% on lymphedema sales surge
Tactile Medical posted strong Q2 2026 results with $85.7 million in revenue and $7.8 million in net income, marking a 142% profit increase. Growth was led by the lymphedema segment, while airway clearance sales dipped temporarily. The company narrowed its annual revenue guidance to $360-$366 million.
3mo agoTactile Medical to release Q2 FY26 financial results on August 10
Tactile Systems Technology, Inc. announced the release of its Q2 FY26 financial results after the market closes on August 10, 2026. A conference call is scheduled for 5:00 p.m. ET on the same day to discuss the results. Participants can join via phone or webcast, with a replay available for two weeks.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Tactile Systems is now worth
$ 90.17
Resulting in a loss of
$ 9.83 (9.83%)
Note: Past profits do not guarantee future returns.
